Value proposition

Pushing the boundaries of biopsy technology

Mursla Bio is a pioneering biotech company on a mission to transform cancer care by pushing the boundaries of biopsy technology. Its breakthrough dynamic biopsy platform combines the strengths of both tissue and liquid biopsies without their limitations in invasiness or biological insights.
Dynamic biopsy is made possible by coupling the latest of extracellular vesicle (EV) and extracellular omics science with Mursla Bio’s pioneering EV technologies.
Mursla Bio’s initial focus is to transform the surveillance of liver cancer in high-risk populations - the fastest growing cause of cancer related deaths.
Mursla Bio is currently conducting a multi-center clinical study to develop its first dynamic biopsy-based blood test, EvoLiverTM.
Mursla Bio is based in Cambridge, UK and Boston, MA

biotech, cancer, diagnostics, proteomics, biomarker, liquid biopsy, oncology, extracellular vesicle, techbio, biology, transcriptomics, computational biology, and liver